Artemis Investment Management LLP grew its stake in Amgen Inc. (NASDAQ:AMGN) by 168.7% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 139,877 shares of the medical research company’s stock after buying an additional 87,822 shares during the quarter. Artemis Investment Management LLP’s holdings in Amgen were worth $24,090,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Canada Pension Plan Investment Board lifted its stake in Amgen by 65.7% during the second quarter. Canada Pension Plan Investment Board now owns 1,706,261 shares of the medical research company’s stock worth $293,869,000 after purchasing an additional 676,300 shares during the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new stake in Amgen during the first quarter worth approximately $110,402,000. Swiss National Bank lifted its stake in Amgen by 26.5% during the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after purchasing an additional 551,600 shares during the last quarter. Bank of Nova Scotia lifted its stake in Amgen by 414.4% during the first quarter. Bank of Nova Scotia now owns 601,862 shares of the medical research company’s stock worth $98,747,000 after purchasing an additional 484,868 shares during the last quarter. Finally, First Eagle Investment Management LLC purchased a new stake in Amgen during the second quarter worth approximately $71,081,000. Institutional investors and hedge funds own 78.15% of the company’s stock.
A number of research firms have recently issued reports on AMGN. BMO Capital Markets reissued a “market perform” rating and issued a $198.00 target price on shares of Amgen in a report on Thursday, October 26th. Cann reissued a “buy” rating on shares of Amgen in a report on Monday, August 28th. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $203.00 target price on shares of Amgen in a report on Thursday, September 7th. Mizuho reissued a “buy” rating and issued a $198.00 target price (up previously from $183.00) on shares of Amgen in a report on Thursday, September 28th. Finally, Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a report on Monday, October 16th. Thirteen research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. Amgen presently has a consensus rating of “Buy” and an average target price of $190.03.
Shares of Amgen Inc. (AMGN) opened at $170.00 on Monday. The company has a market capitalization of $123,404.80, a PE ratio of 13.51, a price-to-earnings-growth ratio of 2.46 and a beta of 1.37. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. Amgen Inc. has a 12 month low of $138.83 and a 12 month high of $191.10.
Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The business had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. During the same quarter last year, the firm earned $3.02 earnings per share. The company’s revenue for the quarter was down .7% compared to the same quarter last year. sell-side analysts anticipate that Amgen Inc. will post 12.66 EPS for the current fiscal year.
Amgen announced that its Board of Directors has authorized a share repurchase plan on Wednesday, October 25th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to reacquire shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s leadership believes its shares are undervalued.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Friday, November 17th will be paid a $1.15 dividend. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.71%. Amgen’s dividend payout ratio (DPR) is currently 41.63%.
In other Amgen news, Director Carbonnel Francois De sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $171.58, for a total value of $261,659.50. Following the sale, the executive vice president now owns 57,631 shares of the company’s stock, valued at approximately $9,888,326.98. The disclosure for this sale can be found here. In the last quarter, insiders sold 7,050 shares of company stock valued at $1,239,673. Insiders own 0.19% of the company’s stock.
WARNING: This piece of content was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/11/20/artemis-investment-management-llp-buys-87822-shares-of-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.